Market Trends of Gynecology Drugs Industry
The Non-hormonal Therapy Segment is Expected to Witness High Growth During the Forecast Period
The non-hormonal therapy segment is expected to have a high growth rate during the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment, rapid advancements in new product development with reduced side effects, and the availability of a wide range of marketed products. Furthermore, the disadvantages of hormonal therapy, such as the risk of breast cancer and other complications associated with these products, are expected to foster the demand for non-hormonal products during the forecast period.
Various studies are being conducted to measure the effectiveness and advantages of non-hormonal therapy. For instance, according to the study published by PubMed in March 2022, NLRP3/IL-1β is involved in the pathogenesis of endometriosis, and the NLRP3 inhibitor may be useful for suppressing ovarian endometriosis and improving the function of ovaries with endometriosis. Thus, significant benefits associated with non-hormonal therapy in gynecological diseases are expected to contribute to the segment's growth during the forecast period.
In addition, increasing clinical trials and launching new non-hormonal therapy drugs for various symptoms are also surging the segment's growth. For instance, in May 2023, Astellas Pharma Inc. announced that the United States Food and Drug Administration (FDA) approved VEOZAHTM (fezolinetant) 45 mg for daily use. This approval is specifically for treating moderate to severe vasomotor symptoms (VMS) resulting from menopause. VEOZAH marks a significant milestone as the inaugural non-hormonal neurokinin 3 (NK3) receptor antagonist is sanctioned for this purpose.
Therefore, increasing studies on non-hormonal therapy and clinical trials are expected to increase awareness of the application of non-hormonal therapy in treating gynecological cancers. Hence, significant segment growth is anticipated during the forecast period.
North America is Expected to Hold a Significant Share in the Market
North America is expected to hold a significant share of the gynecology drugs market during the forecast period. The market is driven by the rising incidences of breast cancer, menopausal disorders, polycystic ovary syndrome, and others due to busy lifestyles and the rise in stress among women in the region.
Moreover, the availability of advanced healthcare infrastructure, an increase in government expenditure for women's healthcare awareness, and the senior women population, along with early product launches with enhanced quality in the region, are expected to contribute to the market's growth during the forecast period.
The growing burden of gynecological diseases in the region is expected to increase demand for effective treatment options, thereby boosting the market's growth. For instance, as per the report published by the Canadian Cancer Society in May 2024, it was estimated that around 1,450 Canadian women would be diagnosed with cervical cancer in 2022. Further, according to the American Cancer Society 2024 report, an estimated 13,820 people in the United States are expected to be diagnosed with invasive cervical cancer in 2024. Thus, the high burden of gynecological cancer among individuals in the United States and Canada is expected to increase demand for gynecological drugs, thereby contributing to the growth of the market during the forecast period.
Key product launches, high concentration of market players or manufacturers' presence, acquisition, and & partnerships among major players are expected to propel the market's growth over the forecast period. For instance, in May 2024, Bayer released data from two advanced-stage studies on elinzanetant, designed to address severe vasomotor symptoms in menopausal women, particularly hot flashes, directly challenging Astellas' established treatment, Veozah. Similarly, in February 2023, GSK PLC announced that the United States Food Drug Administration (FDA) granted full approval for Jemperli to treat adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer.
Such high prevalence and launch of drug treatment is anticipated to surge the demand for gynecology drugs, thereby propelling the market's growth in the United States during the forecast period.
